Greenwich LifeSciences, Inc.
No enriched coverage for $GLSI in the last 7 days.
No SEC Form 4 filings for $GLSI in the last 30 days.
See all $GLSI insider activity →Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
Greenwich LifeSciences Inc (GLSI) stock rose 6.4% to $16.29 in pre-market trading. The company reported Q2 2026 EPS of -$0.27, an improvement from the prior year. Positive clinical trial results, regulatory approvals, and a raised price target by HC Wainwright contributed to the rally. The broader market also showed gains, benefiting small-cap biotech stocks like GLSI.
Premarket trading on Friday shows significant moves in several stocks. RFAI surged 489% to $75.00, SUGP rose 46% to $4.04, and USDE climbed 18% to $4.72. Conversely, DFNS dropped 18% to $20.05, OSIS fell 15% to $186.47, and OPHC declined 11% to $8.21. These early swings may indicate momentum for the regular trading session.
Recent GLSI coverage spans market movers, insider activity and earnings.
Lock‑up extension reduces immediate sell pressure.
Pre‑market price jump reflects positive sentiment from earnings improvement and trial progress.
Biotech stock rises without disclosed data.
Lock‑up extension reduces short‑term dilution risk, supporting price.
Extending the lock-up delays insider and early investor selling, which can support near-term supply/demand and sentiment.
alphai scores every news story that mentions GLSI with an AI model for sentiment and relevance, and aggregates insider trades from Greenwich LifeSciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Eloxx Pharmaceuticals (ELOX) rose 20% after FDA cleared its Phase 2b trial for exaluren. Vogenx (VOGX) gained 14% post-IPO. Arcturus (ARCT) advanced 21% on pipeline updates. Zhengye (ZYBT) +7% after Nasdaq compliance. Greenwich (GLSI) +10% on extended lock-up. HeartSciences (HSCS) +8% after $1M investment. AC Immune (ACIU) +8% on Phase 1 data.
3 min readGreenwich LifeSciences Inc (GLSI) stock rose 6.4% to $16.29 in pre-market trading. The company reported Q2 2026 EPS of -$0.27, an improvement from the prior year. Positive clinical trial results, regulatory approvals, and a raised price target by HC Wainwright contributed to the rally. The broader market also showed gains, benefiting small-cap biotech stocks like GLSI.
2 min readPremarket trading on Friday shows significant moves in several stocks. RFAI surged 489% to $75.00, SUGP rose 46% to $4.04, and USDE climbed 18% to $4.72. Conversely, DFNS dropped 18% to $20.05, OSIS fell 15% to $186.47, and OPHC declined 11% to $8.21. These early swings may indicate momentum for the regular trading session.
1 min readWerewolf Therapeutics (HOWL) rose 90% in after-hours trading, with key clinical trials ongoing. GeoVax (GOVX) gained 12.66%, preparing for a pivotal Phase 3 study. Greenwich LifeSciences (GLSI) increased 6.27%, extending share lock-up. Modular Medical (MODD) up 7.87%, planning Pivot pump rollout. Ovid Therapeutics (OVID) rose 6.93%, with multiple clinical milestones. BioVie (BIVI) up 4.84%, awaiting long COVID data.
2 min readGreenwich LifeSciences (GLSI) shares rose about 5% on Monday after the company said its board extended the lock-up period for directors, officers, and pre-IPO investors through Jan. 31, 2027. The stock traded on Nasdaq around $14.76 to $15.39, after opening at $14.79, with volume below average.
2 min readInvesting.com reported Thursday’s US insider trading roundup. Conagra CEO John Brase bought 35,000 shares for $510,632, and Albertsons CEO Susan Morris bought 39,409 shares for $449,937. CoreWeave CEO Michael Intrator sold about $20.5M, Charles Schwab co-chairman Charles Schwab sold about $15.17M, and Snowflake director Benoit Dageville sold $14M, mostly under 10b5-1 plans.
7 min readGreenwich LifeSciences (NASDAQ:GLSI) CEO/CFO Snehal Patel bought $29,555 of GLSI common stock on July 28-29, 2026, acquiring 2,200 shares at $13.10 to $13.59. Patel is also a director and 10% owner. The stock is down 57% in six months to about $12.80. The company also updated its Phase III FLAMINGO-01 trial after FDA/EMA review.
3 min readPatel Snehal (CEO and CFO) purchased 2,200 shares of Greenwich LifeSciences, Inc. (GLSI) at an average of $13.43 ($13.10–$13.59) across 2 trades over 2026-07-28 to 2026-07-29.
3 min readPatel Snehal (CEO and CFO) purchased 1,500 shares of Greenwich LifeSciences, Inc. (GLSI) at $13.62 on 2026-07-27.
2 min readPatel Snehal (CEO and CFO) purchased 3,600 shares of Greenwich LifeSciences, Inc. (GLSI) at an average of $13.06 ($12.88–$13.14) across 2 trades over 2026-07-23 to 2026-07-24.
2 min read